A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory B-and T-Cell Lymphomas

被引：0
|
作者：
Mehta-Shah, Neha
Moskowitz, Alison J.
Lunning, Matthew A.
Lynch, Peggy
Scheuerman, Mark
Minnal, Veenna
Galasso, Natasha
Kumar, Anita
Gerecitano, John
Zelenetz, Andrew D.
Hamlin, Paul A.
Noy, Ariela
Matasar, Matthew J.
Palomba, Maria Lia
Younes, Anas
Schaffer, Wendy
Grewal, Ravinder
Rademaker, Jurgen
Sauter, Craig S.
Dahi, Parastoo B.
Myskowski, Patricia
Kheterpal, Meenal
Dogan, Ahmet
Pulitzer, Melissa
Lubin, Lakeisha
Tang, Laura
Ganesan, Nivetha
Ni, Ai
Horwitz, Steven M.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
821
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas
    Mehta-Shah, Neha
    Moskowitz, Alison J.
    Lunning, Matthew
    Lynch, Peggy
    Scheuerman, Mark
    Kumar, Anita
    Gerecitano, John F.
    Zelenetz, Andrew D.
    Hamlin, Paul A., Jr.
    Noy, Ariela
    Matasar, Matthew J.
    Palomba, M. Lia
    Younes, Anas
    Schaffer, Wendy
    Grewal, Ravinder
    Rademaker, Jurgen
    Sauter, Craig S.
    Dahi, Parastoo B.
    Myskowski, Patricia
    Kheterpal, Meenal
    Dogan, Ahmet
    Pulitzer, Melissa
    Tang, Laura
    Ni, Ai
    Horwitz, Steven M.
    BLOOD, 2016, 128 (22)
  • [2] A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma.
    Mehta-Shah, Neha
    Lunning, Matthew Alexander
    Boruchov, Adam M.
    Ruan, Jia
    Nair, Sumithra
    Lynch, Peggy
    Byrne, Regina
    Moskowitz, Alison J.
    Matasar, Matthew J.
    Gerecitano, John F.
    Hamlin, Paul A.
    Leonard, John
    Moskowitz, Craig H.
    Myskowski, Patricia L.
    Querfeld, Christiane
    Nolan, Patrick
    Palomba, Maria Lia
    Straus, David J.
    Zelenetz, Andrew David
    Horwitz, Steven M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
    Foss F.
    Coiffier B.
    Horwitz S.
    Pro B.
    Prince H.M.
    Sokol L.
    Greenwood M.
    Lerner A.
    Caballero D.
    Baran E.
    Kim E.
    Nichols J.
    Balser B.
    Wolfson J.
    Whittaker S.
    Biomarker Research, 2 (1)
  • [4] Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma
    Krishnan, Mridula
    Bociek, R. Gregory
    Fanale, Michelle
    Iyer, Swaminathan P.
    Lechowicz, Mary Jo
    Bierman, Philip J.
    Armitage, James O.
    Lunning, Matthew
    Kallam, Avyakta
    Vose, Julie M.
    ANNALS OF HEMATOLOGY, 2022, 101 (02) : 335 - 340
  • [5] Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma
    Mridula Krishnan
    R. Gregory Bociek
    Michelle Fanale
    Swaminathan P. Iyer
    Mary Jo Lechowicz
    Philip J. Bierman
    James O. Armitage
    Matthew Lunning
    Avyakta Kallam
    Julie M. Vose
    Annals of Hematology, 2022, 101 : 335 - 340
  • [6] A Phase 1 Trial of Alisertib and Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas
    Strati, Paolo
    Oki, Yasuhiro
    Fayad, Luis E.
    Nastoupil, Loretta
    Fowler, Nathan H.
    Hagemeister, F. B.
    Kwak, Larry W.
    Lee, Hun Ju
    Wang, Michael
    Westin, Jason R.
    Ruben, Charnelle
    Wesson, Emily
    Fanale, Michelle A.
    BLOOD, 2017, 130
  • [7] A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas
    Strati, Paolo
    Nastoupil, Loretta J.
    Davis, Richard E.
    Fayad, Luis E.
    Fowler, Nathan
    Hagemeister, Fredrick B.
    Kwak, Larry
    Oki, Yasuhiro
    Wang, Michael
    Westin, Jason
    Ruben, Charnelle E.
    Wesson, Emily T.
    Piekarz, Richard
    Fanale, Michelle A.
    Lee, Hun Ju
    HAEMATOLOGICA, 2020, 105 (01) : E26 - E28
  • [8] Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma
    Pro, Barbara
    Horwitz, Steven M.
    Prince, H. Miles
    Foss, Francine M.
    Sokol, Lubomir
    Greenwood, Matthew
    Caballero, Dolores
    Morschhauser, Franck
    Wilhelm, Martin
    Iyer, Swaminathan Padmanabhan
    Shustov, Andrei R.
    Wolfson, Julie
    Balser, Barbara E.
    Coiffier, Bertrand
    HEMATOLOGICAL ONCOLOGY, 2017, 35 (04) : 914 - 917
  • [9] Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma
    Foss, Francine
    Pro, Barbara
    Miles Prince, H.
    Sokol, Lubomir
    Caballero, Dolores
    Horwitz, Steven
    Coiffier, Bertrand
    CANCER MEDICINE, 2017, 6 (01): : 36 - 44
  • [10] A Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas
    Fanale, Michelle A.
    Hagemeister, Fredrick B.
    Fayad, Luis
    Oki, Yasuhiro
    Fowler, Nathan
    Romaguera, Jorge
    Shah, Nina
    Chuang, Hubert
    Feng, Lei
    Horowitz, Sandra B.
    Wesson, Emily
    Hutto, Toni Y.
    Muzzafar, Tariq
    Samaniego, Felipe
    Davis, R. Eric
    BLOOD, 2014, 124 (21)
12345